No CrossRef data available.
Article contents
Actividad de la monoaminooxidasa plaquetaria en el trastorno obsesivo compulsivo
Published online by Cambridge University Press: 01 April 2008
Resumen
La respuesta a los ISRS sugiere que el sistema serotoninérgico está implicado en el trastorno obsesivo compulsivo (TOC). Sin embargo, los estudios biológicos sobre la función serotoninérgica en TOC han dado resultados contradictorios. Se ha propuesto que la actividad monoaminooxidasa (MAO) plaquetaria es un índice de la actividad serotonérgica cerebral.
El objetivo de este estudio fue evaluar la actividad MAO plaquetaria en 29 pacientes con TOC y en 29 controles sanos apareados por edad, sexo y consumo de tabaco. También exploramos la relación entre la actividad MAO plaquetaria y las obsesiones agresivas en pacientes con TOC. No se encontró ninguna diferencia en la actividad MAO plaquetaria entre los pacientes con TOC y los controles sanos.
Encontramos una correlación significativa entre la actividad MAO plaquetaria y las puntuaciones de Y-BOCS en el grupo de pacientes con puntuaciones de Y-BOCS > 15.
Los pacientes con TOC y obsesiones agresivas tenían unos niveles significativamente menores de actividad MAO plaquetaria que los pacientes sin obsesiones agresivas.
Nuestros resultados indican que la actividad MAO plaquetaria puede ser un marcador de la gravedad del TOC, y que la actividad MAO plaquetaria baja puede asociarse con obsesiones agresivas en pacientes con TOC.
- Type
- Artículo original
- Information
- Copyright
- Copyright © European Psychiatric Association 2008
References
Bibliografía
[1]Anthenelli, RMSmith, TLCraig, CETabakoff, BSchuckit, MA. Platelet monoamine oxidase activity levels in subgroups of alcoholas: dlagnostic, temporal, and clinical correlates. Biol Psychiatry 1995; 38: 361-8.CrossRefGoogle ScholarPubMed
[2]Baca-Garcia, ESalgado, BRSegal, HDLorenzo, CVAcosta, MNRomero, MA, et al. A pilot genetic study of the continuum between compulsivity and ¡mpulsivity in females: the serotonin transponer promoter polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2005 Jun; 29(5):713-7.CrossRefGoogle Scholar
[3]Baca-Garcia, EVaquero-Lorenzo, CDiaz-Hernandez, MRodríguez-Salgado, BDolengevich-Segal, HArrojo-Romero, M, et al. Association between obsessive-compulsive disorder and a variable number of tándem repears polymorphism in intron 2 of the serotonin transponer gene. Prog Neuropsychopharmacol Biol Psychiatry 2007 Mar 30;31(2):416-20.CrossRefGoogle Scholar
[4]Blanco, COrensanz-Munoz, LBlanco-Jerez, CSaiz-Ruiz, J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry 1996:153:119-21.Google ScholarPubMed
[5]Carrasco, JLDiaz-Marsa, MHollander, ECesar, JSaiz-Ruiz, J. Decreased platelet monoamine oxidase activity in female bulimia nervosa. Eur Neuropsychopharmacol 2000; 10: 113-7.CrossRefGoogle ScholarPubMed
[6]Cath, DCSpinhoven, PLandman, ADVan Kempen, GM. Psychopathology and personality characteristics in relation to blood serotonin in Tourettets syndrome and obsessive-compulsive disorder. J Psychopharmacol 2001; 15: 111-9.CrossRefGoogle ScholarPubMed
[7]Charney, DSGoodman, WKPrlce, LHWoods, SWRasmussen, SAHeninger, GR. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988; 45: 177-85.Google ScholarPubMed
[8]Conde, V, Franch JL Escalas de evaluación comportamental para la cuantificación de la sintomatología de los trastornos angustiosos y depresivos. Madrid: Upjohn; 1984.Google Scholar
[9]Denys, D, de Geas F, van Megen HJ, Westenberg HG. Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder. Psychiatry Res 2004; 128: 273-80.CrossRefGoogle ScholarPubMed
[10]Flament, MFRapoport, JLMurphy, DLBerg, CJLake, CR. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987; 44: 219-25.CrossRefGoogle ScholarPubMed
[11]Goodman, WKPrice, LHRasmussen, SAMazare, CFleischmann, RLHill, CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-11.CrossRefGoogle ScholarPubMed
[12]Hewlett, WAVinogradov, SMartin, KBerman, SCsernansky, JG. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Res 1992; 42( 1 ): 81–92.CrossRefGoogle ScholarPubMed
[13]Hollander, EDeCarla, CMNitescu, AGully, RSuckow, RFCooper, TB, et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992; 49: 21-8.Google ScholarPubMed
[14]Hollander, EFay, MCohén, B. Serotoninergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioural fmdings. Am J Psychiatry 1988; 145: 1015-7.Google Scholar
[15]Insel, TRMueller, EAAlterman, ILinnoila, MMurphy, DL. Obsessivecompulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985; 20: 1174-88.CrossRefGoogle Scholar
[16]Kaneda, YFujii, ANagamine, I. Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Bial Psychiatry 2001; 25: 983-92.CrossRefGoogle ScholarPubMed
[17]Karno, MGolding, JMSorenson, SBBurnam, MA. The epidemiology of obsessive-compulsive disorder in five US communities. Areh Gen Psychiatry 1988; 45: 1094-9.CrossRefGoogle ScholarPubMed
[18]Meltzer, HYZureick, JL. Relationship of auditory hallucinations and paranoia to platelet MAO activity in schizophrenics: sex and roce interactions. Psychiatry Res 1987; 22: 99–109.CrossRefGoogle Scholar
[19]Muck-Seler, DPivac, NSagud, MJakovljevic, MMihaljevic-Peles, A. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1235-43.CrossRefGoogle ScholarPubMed
[20]Murphy, DLWyatt, RJ. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 1972; 238: 225-6.CrossRefGoogle ScholarPubMed
[21]Pivac, NMuck-Seler, DSagud, MJakovljevic, MMustapic, MMihaljevic-Peles, A. Long-term sertraline treatment and peripheral biochemical markers in female depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 759-65.CrossRefGoogle ScholarPubMed
[22]Sheehan, DVLecrubier, YSheehan, KHAmorim, PJanavs, JWeiller, E, et al. Mini-lntemational Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-1V and ICD-10. J Clin Psychiatry 1998; 59(Suppl. 20): 22-3.Google Scholar
[23]Skondras, MMarídanos, MBotsis, ABistolaki, EChristodoulou, G. Platelet monoamine oxidase activity and psychometric correlates in male violent offenders imprisoned for homicide or other violent acts. Eur Arch Psychiatry Clin Neurosci 2004; 254(+): 380-6.CrossRefGoogle ScholarPubMed
[24]Stahl, SM. In: Longenecker, GS, editor. The platelets physiology and pharmacology. Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons, val. 307. Orlando: Academic; 1985. p. 340.Google Scholar
[25]Stalenheim, EG. Long-term validity of biological markers of psychopathy and criminal recidivism: follow-up 6-8 years after forensic psychiatric investigation. Psychiatry Res 2004; 121(3): 281-91.CrossRefGoogle ScholarPubMed
[26]Sullivan, JLBaenziger, JCWagner, DLRauscher, FPNurnberger, N JrHolmes, JS. Platelet MAO in subtypes of alcoholism. Bial Psychiatry 1990; 27: 911-22.CrossRefGoogle ScholarPubMed
[27] Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281-5.Google Scholar
[28]Verkes, RJPijl, FlMeinders, AEVan Kempen, GM. Borderline personality, impulsiveness, and platelet monoamine mensures in bulimia nervosa and recurrent suicidal behavior. Biol Psychiatry 1996; 40: 173-80.CrossRefGoogle Scholar
[29]Weizman, ACarmi, MHermesh, JJShahar, AApier, ATyano, S, et al. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 1986; 143: 335-9.Google ScholarPubMed
[30]Zohar, JMueller, EAInsel, TRZohar-Kadonch, RCMurphy, DL. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy Controls. Arch Gen Psychiatry 1987; 44: 946-51.CrossRefGoogle ScholarPubMed